Inositol shows real promise for several menopause-related concerns, but the strongest evidence points to metabolic benefits rather than the symptom most women are desperate to fix: hot flushes. Clinical trials in postmenopausal women have found that myo-inositol supplementation can improve insulin sensitivity, blood pressure, and cholesterol markers, all of which tend to worsen after menopause. The picture for vasomotor symptoms like hot flushes and night sweats is muddier, because the studies that show improvement used inositol alongside other active ingredients, making it hard to know what deserves the credit. Still, the metabolic and cardiovascular advantages alone make inositol worth a serious look during this life stage.
Why Menopause Changes Your Metabolism
Before looking at what inositol does, it helps to understand what menopause does. The drop in estrogen during the menopausal transition triggers a cluster of metabolic shifts: fat tends to redistribute toward the midsection, insulin resistance increases, cholesterol profiles change for the worse, and blood vessel function deteriorates.1The Lancet Diabetes & Endocrinology. Cardioprotection, the menopausal transition, and the prevention of cardiovascular disease These changes add up. Menopause significantly raises the risk of type 2 diabetes, cardiovascular disease, metabolic syndrome, and non-alcoholic fatty liver disease.2PubMed Central. Metabolic Disorders in Menopause The metabolic syndrome risk in particular tends to escalate gradually as women move through the transition, with some populations experiencing more rapid progression than others.3PubMed Central. Progression of Metabolic Syndrome Severity During the Menopausal Transition
This is the context that makes inositol interesting. Myo-inositol is a naturally occurring sugar alcohol that plays a role in insulin signaling and cellular communication. When the body’s ability to process insulin declines, as it does during menopause, having adequate inositol available appears to help keep the metabolic machinery running more smoothly. Low inositol levels have been linked to conditions like weight gain, elevated insulin, abnormal lipids, and metabolic syndrome.4PubMed Central. Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies
Insulin Resistance and Metabolic Syndrome
The most convincing evidence for inositol in menopause comes from trials targeting metabolic syndrome, a cluster of conditions including high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol that commonly emerges after menopause. In a randomized, placebo-controlled study of postmenopausal women with metabolic syndrome, myo-inositol combined with dietary changes outperformed diet and placebo alone on nearly every metabolic marker. The myo-inositol group saw about an 11% drop in diastolic blood pressure, a roughly 75% improvement in insulin resistance (measured by HOMA index), a 20% reduction in triglycerides, and a 22% increase in HDL (“good”) cholesterol.5PubMed. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study
A follow-up study tracked postmenopausal women with metabolic syndrome for a full year. After 12 months of myo-inositol supplementation, all measured parameters except BMI and waist circumference improved significantly compared to the control group. By the end of the study, about one in five women in the myo-inositol group no longer met the criteria for metabolic syndrome, compared to essentially none in the control group.6PubMed. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome That is a meaningful clinical outcome: not just improving numbers on a lab report, but actually resolving the condition for some women.
The fact that BMI and waist circumference did not budge is worth noting. Inositol does not appear to be a weight-loss tool in the direct sense. Its metabolic benefits seem to operate through improving how the body handles insulin and processes fats, even if the number on the scale stays put.
Cholesterol and Cardiovascular Markers
A systematic review and meta-analysis pooling data from randomized controlled trials found that inositol supplementation in people with metabolic diseases led to meaningful reductions in triglycerides, total cholesterol, and LDL (“bad”) cholesterol. However, the same analysis found no significant effect on HDL cholesterol.7PubMed Central. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials This is somewhat at odds with the individual postmenopausal trial described above, which did show HDL improvements. The discrepancy likely reflects differences in the populations studied: the meta-analysis included a broader range of metabolic conditions, not exclusively postmenopausal women.
For women in the menopausal transition, the lipid-lowering effects matter because cardiovascular risk rises steeply after menopause. Anything that keeps triglycerides and LDL in check without the side-effect profile of a pharmaceutical intervention has practical value. Inositol is not a substitute for statins in women who already have clinically elevated cardiovascular risk, but for the many women who are drifting into borderline territory during the transition, it represents a low-risk intervention that might help keep lipids from sliding further.
Hot Flushes and Night Sweats
This is where the evidence gets tricky. One retrospective study of menopausal women with metabolic syndrome reported impressive improvements in hot flushes after six months: the proportion of women experiencing frequent episodes (four to nine per day) dropped from about 54% to 18%, and no women reported severe hot flushes at the end of the study compared to a small percentage at the start. Night sweats showed similar improvements, with moderate-severity episodes dropping from 87% to 30%.8PubMed Central. Dietary Supplementation of Myo-Inositol, Cocoa Polyphenols, and Soy Isoflavones Improves Vasomotor Symptoms and Metabolic Profile in Menopausal Women with Metabolic Syndrome
The problem is that the supplement used in that study was a combination of myo-inositol, cocoa polyphenols, and soy isoflavones. Soy isoflavones are phytoestrogens with their own body of evidence for reducing hot flushes. There is no way to untangle from this study design how much of the vasomotor relief came from inositol and how much came from the soy or the cocoa. Until a trial tests myo-inositol alone against a placebo and measures hot flush frequency as the primary outcome, the honest answer is that we do not know whether inositol by itself helps with hot flushes. It might, but we cannot point to a clean study confirming it.
If you are considering inositol primarily for hot flushes and night sweats, temper your expectations. The metabolic benefits are well-established; the vasomotor symptom relief is plausible but unproven for inositol on its own.
Mood and Depression
The same combination-supplement study noted above also tracked depression symptoms. Before supplementation, about 87% of the women reported moderate depressive symptoms. After six months, that figure dropped to 56%.8PubMed Central. Dietary Supplementation of Myo-Inositol, Cocoa Polyphenols, and Soy Isoflavones Improves Vasomotor Symptoms and Metabolic Profile in Menopausal Women with Metabolic Syndrome The same caveat applies: this was a multi-ingredient supplement, not inositol alone. But there is a broader reason to pay attention. Inositol is involved in the signaling pathways of serotonin and other neurotransmitters, and it has been studied in other contexts for anxiety and panic disorder, usually at higher doses than the ones used in menopause trials. The idea that it could help with the mood disruptions common during menopause is biologically coherent, even if the menopause-specific evidence is still entangled with confounders.
Mood changes during menopause are notoriously hard to study, because they overlap with sleep disruption, life stressors, and hormonal fluctuations that are difficult to control for. Women who notice mood improvements while taking inositol may be benefiting from the direct neurochemical effects, from better sleep due to fewer night sweats, from improved metabolic health (which itself affects mood), or from some combination. Disentangling these pathways is a research challenge that has not been fully addressed yet.
Thyroid Function During the Transition
Thyroid problems become more common as women age, and the menopausal transition is a period when subclinical thyroid dysfunction often surfaces. One study compared myo-inositol alone to myo-inositol combined with melatonin in women going through the menopausal transition. An interesting divergence emerged: TSH (the hormone that rises when thyroid function is sluggish) decreased in the myo-inositol-only group but increased in the group taking the combination. Meanwhile, insulin levels fell in both groups. This suggests that myo-inositol on its own may have a positive effect on thyroid function, though the study was small and the finding needs replication.
The thyroid angle is relevant because hypothyroid symptoms (fatigue, weight gain, brain fog, depressed mood) overlap heavily with menopause symptoms. A woman who attributes all of her symptoms to menopause might actually have a concurrent thyroid issue. If inositol helps support thyroid function while also addressing insulin resistance, it could be addressing two problems that many women do not realize they have simultaneously.
Bone Health
Osteoporosis is one of the major long-term consequences of estrogen loss after menopause. The evidence for inositol’s role in bone health is still largely preclinical, meaning it comes from animal models and cell studies rather than clinical trials in humans. In ovariectomized mice (a standard model for postmenopausal osteoporosis), a derivative of inositol called D-pinitol improved bone calcium and phosphorus content. The mechanism appeared to involve reducing the activity of osteoclasts, the cells that break down bone, rather than boosting the cells that build it.9PubMed Central. Inositols and Bone Health: Potential Therapeutic Applications in Osteoporosis Prevention and Treatment
Cell-culture studies have shown mixed results depending on the type of cells used. One study found that IP6 (inositol hexakisphosphate, a different inositol form) decreased bone-building markers in one cell line but increased them in human stem cells, which complicates the picture considerably.10Cellular Physiology and Biochemistry. Differential Response of MC3T3-E1 and Human Mesenchymal Stem Cells to Inositol Hexakisphosphate The researchers themselves note that further studies are needed to understand the net effect on bone formation.
In short, there are plausible biological reasons to think some forms of inositol could support bone health after menopause, but this is early-stage science. No one should take inositol as a bone-loss prevention strategy based on current evidence. Standard recommendations for bone health during and after menopause, including adequate calcium and vitamin D intake, weight-bearing exercise, and bone density monitoring, remain far better supported.
Which Form and How Much
Inositol comes in several forms, but the two that matter most clinically are myo-inositol and D-chiro-inositol. Most of the menopause-relevant research has used myo-inositol, typically in the range of 2 to 4 grams per day. Myo-inositol is the form that predominates in the body and is the one with the most clinical trial data behind it.
D-chiro-inositol is a less abundant form that also acts on insulin signaling but through somewhat different mechanisms. The two forms are often combined. An international consensus, developed largely in the context of PCOS research, settled on a ratio of 40 parts myo-inositol to 1 part D-chiro-inositol as reflecting the physiological balance seen in humans.11Gynecologic and Obstetric Investigation. d-Chiro-Inositol in Clinical Practice: A Perspective from the Experts Group on Inositol in Basic and Clinical Research (EGOI) That 40:1 ratio has been shown in PCOS studies to produce better outcomes than myo-inositol alone, particularly in overweight patients.12PubMed. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS
Whether the 40:1 ratio is optimal for postmenopausal women specifically has not been established by a dedicated trial. Most researchers extrapolate from the PCOS and metabolic syndrome data, which is reasonable given the shared insulin-resistance pathway. If you are choosing a supplement, look for myo-inositol as the primary ingredient. Products that combine the two forms in the 40:1 ratio are widely available and consistent with the current expert consensus, though the evidence base for that ratio was built in younger women with PCOS, not in postmenopausal populations.
Combining Inositol with Other Nutrients
Some studies have tested inositol in combination with other compounds. One placebo-controlled trial combined inositol with alpha-lipoic acid in women with metabolic syndrome. After six months, about two-thirds of the treatment group saw a meaningful drop in insulin resistance, and close to 90% experienced a decrease in serum insulin levels. The treatment group also showed modest improvements in HDL cholesterol and triglycerides.13PubMed Central. Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial Alpha-lipoic acid is itself an antioxidant with some evidence for improving insulin sensitivity, so the combination may offer additive benefits.
The pattern across these studies is consistent: when inositol is paired with other bioactive compounds, the results tend to be positive. But the combination-supplement design makes it difficult to credit inositol specifically. For a consumer, this is actually somewhat useful information. If you are already taking or considering alpha-lipoic acid, soy isoflavones, or other supplements for menopause-related metabolic concerns, adding inositol is likely to complement rather than conflict with those interventions. Just be aware that the impressive results from combination studies cannot be assumed to come from inositol alone.
What Inositol Cannot Replace
For women with severe hot flushes, hormone replacement therapy (HRT) remains the most effective treatment, and inositol does not have the evidence to challenge that. HRT directly addresses the estrogen deficit driving vasomotor symptoms. Inositol works through entirely different mechanisms, primarily insulin signaling, and does not raise or mimic estrogen levels. If your primary concern is debilitating hot flushes or vaginal dryness, inositol is unlikely to be a sufficient solution on its own.
Inositol is also not a replacement for pharmaceutical management of diabetes, high blood pressure, or severely elevated cholesterol. The improvements seen in trials are meaningful in the context of prevention and early-stage metabolic syndrome, not in the context of managing established disease. A woman whose blood pressure or blood sugar is already in a clinical range that requires medication should not rely on inositol instead.
Where inositol may find its niche is in the large group of women whose metabolic numbers are drifting in the wrong direction during the menopausal transition but who do not yet qualify for, or prefer to avoid, pharmaceutical intervention. For that group, the evidence genuinely supports trying it, particularly given its favorable safety profile. Gastrointestinal discomfort at higher doses (nausea, bloating, loose stools) is the most commonly reported side effect, and it tends to resolve with dose adjustment.
Dietary Sources Versus Supplements
Your body makes some myo-inositol on its own, primarily in the kidneys, and you get additional amounts from food. Fruits, beans, grains, and nuts are all dietary sources. However, the doses used in clinical trials (typically 2 to 4 grams per day) are substantially higher than what most people consume through diet alone. A typical Western diet provides somewhere around 1 gram of inositol per day. If you eat a lot of citrus fruit, cantaloupe, and legumes, you may get somewhat more, but reaching therapeutic levels through food alone is impractical.
Supplemental myo-inositol usually comes as a powder that dissolves in water, which makes dosing flexible. It has a mildly sweet taste. Capsule forms are available but often require taking several pills to reach the doses used in research. The powder form is generally more convenient and less expensive if you are aiming for multi-gram daily doses. Splitting the dose into two servings (morning and evening) is a common approach in clinical practice, though no trial has specifically compared split versus single dosing in menopausal women.
The Research Gaps
The evidence for inositol in menopause is encouraging but genuinely thin in certain areas. Most trials have been small, ranging from a few dozen to about a hundred participants. Several are retrospective rather than randomized. The metabolic syndrome data is the most robust, with both short-term and year-long follow-up in placebo-controlled designs. But the vasomotor symptom data, mood data, and thyroid data each rest on one or two small studies with methodological limitations.
There is also a notable gap around timing. We do not know whether starting inositol during perimenopause (before the full metabolic shift occurs) produces better outcomes than starting after menopause. Most trials enrolled postmenopausal women who already had metabolic syndrome. Whether inositol could prevent metabolic syndrome from developing in the first place is an unanswered question, though the mechanism of action makes it a reasonable hypothesis.
Women who had PCOS earlier in life may be especially interested in inositol during menopause, because PCOS is itself characterized by insulin resistance and metabolic dysfunction. The transition into menopause can worsen these already-existing vulnerabilities. Inositol is well-studied for PCOS in reproductive-age women, and the metabolic rationale carries over into the postmenopausal period, even though no trial has specifically enrolled women with a PCOS history and followed them through menopause. If you fall into this group, discussing inositol with your healthcare provider is a reasonable conversation to have.